Chemed Corp (CHE) Stock Price & Analysis
Chemed Corp (CHE) rose 1.62% to USD 446.26 as of June 10, 2026 at 03:28 UTC, according to Nexqual real-time market data.
CHE last closed at USD 439.13; the session ranged USD 440.25–449.21 on volume of 142,736 shares. Market capitalization is $5.92B, with a 52-week range of USD 365.21–562.77 (NYQ). Source: Nexqual, June 10, 2026 at 03:28 UTC.
Key Statistics (as of June 10, 2026 at 03:28 UTC)
| Price | USD 446.26 |
|---|---|
| Change | ▲ 1.62% (up) |
| Previous Close | USD 439.13 |
| Open | USD 440.77 |
| Day Range | USD 440.25 – 449.21 |
| 52-Week Range | USD 365.21 – 562.77 |
| Volume | 142,736 shares |
| Market Cap | $5.92B |
| Exchange | NYQ |
Technical Analysis (CHE)
Nexqual's technical model rates CHE "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:28 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 69.11 (neutral) |
| vs SMA50 | Above (USD 412.91) |
| MACD | 5.76 (positive) |
Analyst Ratings (CHE)
Wall Street analysts rate CHE "Buy" based on 4 analysts, with a mean price target of USD 446.5 (range USD 400–500), per Nexqual as of June 10, 2026 at 03:28 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 446.5 |
| High Target | USD 500 |
| Low Target | USD 400 |
| Buy / Hold / Sell | 1 / 3 / 0 |
Earnings (CHE)
| Next Earnings Date | 2026-04-23 |
|---|---|
| EPS Estimate | USD 5.62 |
| Revenue Estimate | $665.53M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 5.65 vs est 5.3 ▲ beat |
| 2025-12-31 | USD 6.42 vs est 7.03 ▼ miss |
| 2025-09-30 | USD 5.27 vs est 5.37 ▼ miss |
| 2025-06-30 | USD 4.27 vs est 4.98 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Financials & Fundamentals (CHE)
| Total Revenue | $2.54B |
|---|---|
| Revenue Growth (YoY) | +1.60% |
| Gross Margin | +32.38% |
| Operating Margin | +12.86% |
| Profit Margin | +10.22% |
| ROE | +25.60% |
| Debt / Equity | 27.94 |
| Current Ratio | 0.85 |
| Total Cash | $16.86M |
| Total Debt | $236.93M |
| Free Cash Flow | $348.26M |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Financial Health Score (CHE)
Nexqual rates Chemed Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 03:28 UTC.
| Growth | Mixed — Revenue +4.1% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 32%, operating 13% |
| Balance Sheet | Solid — $17M cash vs $237M debt |
| Cash Flow | Solid — FCF $348M, 14% margin |
| Efficiency | Strong — ROE 26%, ROA 12.8% |
Ownership (CHE)
| Insider Ownership | +2.06% |
|---|---|
| Institutional Ownership | +104.14% |
| Shares Outstanding | 13.27M |
| Float | 12.99M |
| Short % of Float | +5.64% |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Leadership (CHE)
Chemed Corp is led by Kevin J. McNamara (age 71), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:28 UTC.
| CEO, President & Director | Kevin J. McNamara (age 71) |
|---|---|
| Executive VP, Controller, Principal Accounting Officer & CFO | Michael D. Witzeman (age 54) |
| Executive Vice President | Spencer S. Lee (age 69) |
| VP & Director | Thomas C. Hutton (age 74) |
| Executive VP and President & CEO of VITAS Healthcare | Joel L. Wherley (age 60) |
Major Backers & Investors (CHE)
Notable institutional backers of Chemed Corp include JPMorgan, AQR Capital Management, LLC, Acadian Asset Management. LLC, according to Nexqual as of June 10, 2026 at 03:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 3.77% |
| AQR Capital Management, LLC | 3.13% |
| Acadian Asset Management. LLC | 2.31% |
| Two Sigma Investments, LP | 2.27% |
| TD Asset Management, Inc | 2.11% |
| J.P. Morgan Fleming Mutual Fd. Group, Inc.-JPMorgan Mid Cap Value Fd. | 1.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.37% |
| BlackRock | 13.67% |
| State Street | 4.29% |
| Geode Capital | 3.1% |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
From Chemed Corp's Latest SEC 10-K Filing (filed 2026-02-27)
Partnerships
- Violations of the Anti-Kickback Law carry potentially severe penalties including imprisonment of up to ten years, criminal fines of up to $100,000 per act, civil money penalties of up to $100,000 per act, and additional damages of up to three times the amounts claimed or remuneration offered or paid.
- The Company denied any violation of law and agreed to settlement without admission of wrongdoing.   8 In connection with the settlement, VITAS and certain of its subsidiaries entered into a corporate integrity agreement ("CIA") on October 30, 2017.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSG | The Ensign Group, Inc. | USD 155.25 | ▼ 8.84% |
| EHC | Encompass Health Corporation | USD 104.19 | ▲ 0.17% |
| ATR | AptarGroup, Inc. | USD 115.9 | ▲ 2.24% |
| WST | West Pharmaceutical Services, I | USD 334.66 | ▲ 6.41% |
| CRL | Charles River Laboratories Inte | USD 189.85 | ▲ 4.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:28 UTC. This page is informational and not investment advice.